MENA With a healthcare system marked by both progress and difficulties due to the country’s economic overreliance on the oil and gas sector and its recent political instability, Algeria, is the second largest pharma market on the African continent. Recent reforms have also sped up drug approvals and are turning the…

Opinion In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for a more robust regulatory framework in Algeria and even the creation of a unified FDA-style regulator to counter this threat…

Algeria Below we present recent news from Algeria’s pharmaceutical industry, including the creation of a dedicated Ministry to boost the sector, changes to the advertising rules for dietary supplements, and local medical device manufacturers’ efforts in the fight against COVID-19.   Government: Broad prerogatives for the newly created Ministry of Pharmaceutical…

Algeria Yacine Sellam examines how pharmacists in Algeria can follow the lead of their US counterparts and play a greater role in patients’ diabetes management.   Noncommunicable diseases are a growing burden in Algeria. The results of a STEPwise survey revealed that, for adults aged between 18 and 69 years, 23.6…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, looks at how European countries such as France and Belgium have countered medicine supply shortages and how Algeria can implement these solutions to address its own drug shortage issue.    This situation is not unique to Algeria. Medicine…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, examines Algeria’s recent issues around medicine shortages, its root causes, and the measure being taken to counter it.   The smooth operation of the drug distribution chain in Algeria is compromised by its multiplicity of actors – from…

Algeria Yacine Sellam, president of the Algerian Society for Regulatory Affairs & Pharmacoeconomics, outlines the progress made under Algeria’s National Cancer Plan and the steps that still need to be taken to ensure all Algerian cancer patients can receive the care they need.   It is undeniable that tangible progress has…

Algeria Click here to download the Healthcare & Life Sciences Review Algeria 2019 report.   Algeria, Africa’s largest country by area, stands as a promising investment destination for the global life sciences industry, with a sizeable local market and a growing number of multinationals choosing to base their regional operations out…

Algeria With stiffening up of local content requirements well underway, many multinational drug developers seeking to introduce their therapies to the Algerian marketplace have been scrambling to team up with the handful of indigenous CMOs that possess the requisite quality standards and reputations to handle their brands. Here is a selection…

Algeria

Algeria Key recent investments from Middle Eastern companies into Algerian Pharma.   Saudi company Tabuk Pharmaceuticals invests USD 20 million into a plant in Blida (2014) “We arrived in Algeria in 1997 with imports only. Then Tabuk partnered with the Central Pharmacy of Hospitals (PCH) in 2004. We had a renewed…

Algeria A sudden imposition of import restrictions on pharmaceuticals in 2017 has pushed several multinational companies to establish local production facilities in Algeria. However, the localization process can be fraught both for companies that establish direct manufacturing footprints via joint ventures and those that employ the services of local contract manufacturers.…